ADVERTISEMENT
ADVERTISEMENT
Chinmay Jani wins 2026 award for lung cancer research
Dr. Jani has contributed to multicenter studies across lung cancer, prostate cancer and liquid biopsy development, and his work has been presented at major international meetings including ASCO, AACR, WCLC and NANETS.
-
1759953093.png)
Staff Reporter - Thu, 13, Aug 2026
- 04:02 EDT
- 17
Chinmay Jani / X@Chinmay Jani
Indian-origin oncology researcher Dr. Chinmay Jani has been awarded the 2026 Impact Pitch Lung Cancer Research Award by the Binay Tara Foundation for research aimed at overcoming treatment resistance and improving therapeutic outcomes for non-small cell lung cancer (NSCLC).
Dr. Jani, chief fellow in hematology and oncology at the Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital, University of Miami, specializes in thoracic oncology, pulmonary neuroendocrine tumors and early-phase drug development. His research focuses on novel immunotherapy combinations, biomarkers such as TEM8 and microbiome-based predictors of response, and the design of investigator-initiated Phase I/II trials.
The award will fund an investigator-initiated trial focused on non-small cell lung cancer (NSCLC). The study explores how modulating the gut microbiome can enhance the efficacy of immunotherapy and establish a longitudinal multi-omic biobank to track molecular and biological changes in patients over time.
“Extremely grateful and honored to receive the Binay Tara 2026 Impact Pitch Lung Cancer Research Award!” Dr. Jani said on X. “This support will advance our NSCLC IIT exploring gut microbiome modulation with immunotherapy and establish a longitudinal multi-omic biobank.”
Extremely grateful and honored to receive the @binaytara 2026 Impact Pitch Lung Cancer Research Award!
Chinmay Jani wins 2026 award for lung cancer research
Dr. Jani has contributed to multicenter studies across lung cancer, prostate cancer and liquid biopsy development, and his work has been presented at major international meetings including ASCO, AACR, WCLC and NANETS. He serves as a sub-investigator on multiple first-in-human studies evaluating emerging immunotherapies, ADCs, bispecifics and oncolytic viruses.
Beyond clinical research, Dr. Jani is deeply involved in academic programming and trainee education, having developed multiple institutional initiatives, journal club series and statewide quality-improvement projects through FLASCO. His work has been featured in peer-reviewed journals, oncology media outlets and national research networks. He is committed to advancing precision oncology and developing novel therapeutics to improve outcomes for patients with cancer.
Discover more at New India Abroad.
Leave A Comment
Related
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login